Combinatorial Pharmacogenetics

@article{Wilke2005CombinatorialP,
  title={Combinatorial Pharmacogenetics},
  author={Russell A. Wilke and David M. Reif and Jason H. Moore},
  journal={Nature Reviews Drug Discovery},
  year={2005},
  volume={4},
  pages={911-918}
}
Combinatorial pharmacogenetics seeks to characterize genetic variations that affect reactions to potentially toxic agents within the complex metabolic networks of the human body. Polymorphic drug-metabolizing enzymes are likely to represent some of the most common inheritable risk factors associated with common 'disease' phenotypes, such as adverse drug reactions. The relatively high concordance between polymorphisms in drug-metabolizing enzymes and clinical phenotypes indicates that research… 
Mapping genes that predict treatment outcome in admixed populations
TLDR
The current review explores analytical strategies that leverage population structure to more fully characterize genetic determinants of outcome in large clinical practice-based cohorts.
Systems biology approaches in asthma pharmacogenomics study
TLDR
It is likely that the combination of network modeling, functional validation, and integrative -Omics will be needed to move asthma pharmacogenomics closer to clinical relevance.
Cytochrome P450 gene-based drug prescribing and factors impacting translation into routine clinical practice.
TLDR
The common cytochrome P450 gene polymorphisms are reviewed and the factors that may facilitate (or attenuate) their translation into clinical practice are discussed.
Biobanking and pharmacogenomics.
TLDR
Longitudinal data available in practice-based datasets will position investigators to characterize genetic factors with small but reproducible effects on drug outcome in the context of gene-environment interactions.
Adverse Drug Reaction to Methotrexate: Pharmacogenetic Origin
TLDR
A case in which a standard dose of methotrexate resulted in life-threatening mucositis, neutropenia, and thrombocytopenia in a 61-year-old woman was reported, found to have a genetic anomaly in an enzyme that plays a key role in folate metabolism.
Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.
TLDR
A genetic interaction between the TYMS enhancer region and VEGF +405G>C polymorphisms as a predictor of the efficacy of CAPOX-B in mCRC patients is supported.
Editorial: Insights in Pharmacogenetics and Pharmacogenomics: 2021
The main aim of this Research Topic is to shed light on recent progress in the Pharmacogenetics and Pharmacogenomics field as well as current and future challenges, aiming to provide a thorough
Use of Biological Knowledge to Inform The Analysis of Gene-Gene Interactions Involved in Modulating Virologic Failure with Efavirenz-Containing Treatment Regimens in Art-Naive Actg Clinical Trials Participants
TLDR
The utility of the Biofilter method to prioritize the search for gene-gene interactions in large-scale genomic datasets is demonstrated, although replication in a larger cohort is required to confirm the validity of this particular TAP1-ABCC9 finding.
Translational pharmacogenetics and risk management in the cardiovascular arena: CYP3A5*3 model for gene-based drug selection.
  • R. Wilke
  • Biology
    Personalized medicine
  • 2006
TLDR
Four potential reasons why the clinical and scientific communities should consider including CYP3A5*3 in any panel of gene polymorphisms developed for the purpose of guiding cardiovascular pharmacotherapy are explored.
[Cardiovascular pharmacogenomics].
...
...

References

SHOWING 1-10 OF 81 REFERENCES
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
TLDR
Combinations of polymorphisms in pharmacokinetic and pharmacodynamic pathways of relevance might contribute to identify genotypes associated with best and worst responders and they may also identify susceptibility to adverse drug reactions.
Cytochrome P450 gene-based drug prescribing and factors impacting translation into routine clinical practice.
TLDR
The common cytochrome P450 gene polymorphisms are reviewed and the factors that may facilitate (or attenuate) their translation into clinical practice are discussed.
Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy
TLDR
It is likely that predictive genotyping is of benefit in 10-20% of drug treatment and thereby allows for prevention of causalities as a cause of ADRs and thus improves the health for a significant fraction of the patients.
Genomics and Drug Toxicity
TLDR
The development and acceptance of toxicogenomic data submission standards promise to significantly improve the drug risk assessment process, which would benefit the pharmaceutical industry and public alike.
Characterization of cytochrome P450 2D6 alleles using the Invader system.
TLDR
A comprehensive CYP2D6genotyping strategy that employs both a PCR/Invader genotyping assay system and an Invader genomic copy number assay is described, which is a homogeneous, isothermal, highly specific, and robust signal amplification system.
Computational analysis of gene-gene interactions using multifactor dimensionality reduction
  • J. Moore
  • Biology
    Expert review of molecular diagnostics
  • 2004
TLDR
A novel strategy known as multifactor dimensionality reduction that was specifically designed for the identification of multilocus genetic effects is presented and several case studies that demonstrate the detection of gene–gene interactions in common diseases such as atrial fibrillation, Type II diabetes and essential hypertension are discussed.
Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer.
One of the greatest challenges facing human geneticists is the identification and characterization of susceptibility genes for common complex multifactorial human diseases. This challenge is partly
STUDENTJAMA. The challenges of whole-genome approaches to common diseases.
TLDR
Powerful statistical and computational methods will need to be developed to model the relationship between combinations of SNPs and disease susceptibility, which suggests several challenges in identifying susceptibility genes from the entire human genome.
...
...